Ophthalmic Drug Delivery
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/400,864, filed Jul 15, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,087,145 | Ophthalmic Drug Delivery In force · High confidence | Hyperion Defi, Inc. | In force | High confidence | ||
| US 10,073,949 | Ophthalmic Drug Delivery In force · Medium confidence | Hyperion Defi, Inc. | In force | Medium confidence | ||
| US 10,839,960 | Ophthalmic Drug Delivery In force · Medium confidence | Hyperion Defi, Inc. | In force | Medium confidence | ||
| US 11,398,306 | Ophthalmic Drug Delivery In force · Medium confidence | Hyperion Defi, Inc. | In force | Medium confidence | ||
| US 11,839,487 | Ophthalmic Drug Delivery In force · Medium confidence | Hyperion Defi, Inc. | In force | Medium confidence | ||
| US 12,490,932 | Ophthalmic Drug Delivery In force · Medium confidence | Hyperion Defi, Inc. | In force | Medium confidence | ||
| Application 14/793,895 | Ophthalmic Drug Delivery Abandoned Abandoned Mar 23, 2017 | Hyperion Defi, Inc. | Abandoned | Abandoned Mar 23, 2017 |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Hyperion Defi, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.